The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019

Sun Pharma Q2 results: The drugmaker, which earns 37 per cent of its business from the US market, earned Rs 2,389.77 crore from the sale of formulations in the US in Q2FY20 against Rs 2397 crore in the corresponding quarter of the previous year

Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year

The collateral damage of the United States' trade wars is being felt around the world as President Donald Trump renegotiates relationships with many of Washington's top trading partners.

The communication also directed the state-level authorities to communicate to the DCGI at the earliest on the action initiated by them.

The super rich are pumping enormous amounts of money into research that will extend life - and keep death at bay for a long, long time...

Ranitidine, an old molecule with sales of $412.4 million is found to have cancer-causing impurities

Even as smaller Indian companies are looking to grow their business in the US market, the larger focus is on leading pharma companies because the top 20 of them contribute 75 per cent to total pharma exports from India

Given the low cost of electricity, favourable weather conditions and water availability, industry players feel that Jammu & Kashmir can be an important manufacturing hub of pharmaceutical companies

Zydus Cadila, India's fourth-largest drug company by revenue, is banking big on research of new drugs, even though others have bowed out. Zydus expects the new drug business to grow to Rs 3,500 crore in four-five years

Japanese firms have generally cracked the code of working in India's huge domestic market, but the extent of success varies

Indian companies are finally getting down to cracking the Japanese market

The U.S. Food and Drug Administration (FDA) said it found adulteration and \"significant violations\" of current good manufacturing practice (CGMP) regulations at Strides Pharma Sciences Ltd's plant in Puducherry in south India.

The path to product and profitability for stem cell players is fraught with challenges

This plant had five USFDA inspections between March 2015 and September 2018 with no observations and receiving an EIR after each inspection visit

India for long has been pressing China to open its huge pharmaceutical market, which is under pressure from the public for the high prices for cancer and generic drugs